Introduction
Oesophageal squamous cell carcinoma (OSCC), the major histological form of oesophageal cancer, is the sixth most frequent cause of cancer deaths worldwide. OSCC shows a poor prognosis because of the lack of an early screening strategy and often presents at an advanced stage at the time of diagnosis. 1 The clinicopathological stage and histological grade are the most important factors for determining clinical outcomes in OSCC. Groups of patients with similar stages or histological grades of the disease tend to differ noticeably in survival rate. Several new prognostic factors, such as the proteins p53, 2 cyclin D1 3 and the nuclear antigen Ki-67, 4, 5 have been evaluated in the hope that they may provide a better assessment of survival probability and, therefore, contribute to the tailoring of treatments for individual patients. Whether these factors can be successfully used as prognostic indicators remains elusive, although they do seem to be involved in the initiation of OSCC. 5 -7 Thus, there is a clear need to find new molecular prognostic markers that can help to identify patients who have a relatively high risk of death.
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members of the G-protein-coupled receptor family, which have seven helical hydrophobic transmembrane domains. To date, four receptor subtypes, PAR-1, -2, -3 and -4, have been identified, and each is activated in a protease-dependent manner. 8 PAR-1, -3 and -4 are cleaved and activated by thrombin, whereas PAR-2 is activated by trypsin and trypsin-like proteases, including some coagulation factors. 9 The PAR-2 gene is expressed in various tissues, including skin, pancreas, gastrointestinal tissue, ovary, kidney and liver. 10 It is also expressed in endothelial cells, fibroblasts, neurons, smooth muscle cells and airway epithelium cells. 10,11 PAR-2 is implicated in the acute and chronic responses associated with vascular tone, inflammation, coagulation and wound healing. 12 It has been reported that PAR-2 plays an important role in invasion and tumour growth in different malignant neoplastic diseases, such as breast, stomach, colon, prostate and pancreatic cancers. 13 -19 Expression of PAR-2 in cancer cells, implying a poor prognosis, has been linked to breast and nasopharyngeal carcinoma. 20, 21 Little attention has been paid to the question of whether PAR-2 is responsible for the invasion and metastasis of OSCC. In the present study, the expression of PAR-2 in OSCC was investigated by immunohistochemistry and the prognostic value of PAR-2 for OSCC was analysed using Kaplan-Meier survival curves.
Materials and methods

TISSUE SAMPLES
A total of 205 surgically resected primary OSCC specimens, obtained between April 2001 and August 2003, were retrieved from the archives of The First Affiliated Hospital of Zhengzhou University (Zhengzhou, China). The specimens had been fixed with formalin and embedded in paraffin. Tumour stage was classified according to the tumour, node, metastasis classification of the American Joint Committee on Cancer. 22 Post-operative treatments comprised only follow-up, radiotherapy, chemotherapy, or both radiation and chemotherapy. Recurrence and survival data were obtained from the Department of Oncology, The First Affiliated Hospital of Zhengzhou University. Case selection for inclusion in the study was based on a review of haematoxylin and eosinstained sections of the tumour to confirm the histopatho logical diagnosis and to establish that sufficient tissue was available to generate tissue microarrays (TMAs).
This study was approved by the institutional review board of the First Affiliated Hospital of Zhengzhou University. All patients providing samples for the study were required to have provided written informed consent for their specimens to be used for scientific research.
PREPARATION OF TMAS
The TMAs were constructed as described previously. 23 In brief, viable and representative areas of tumour on haematoxylin and eosin-stained sections were identified and marked by a pathologist. The corresponding region of the source block was cored, and 1-mm cores were then transferred to recipient master blocks using a tissue arrayer (Gentury Biomedical, Medford, MA, USA). Three to six cores of each specimen were examined simultaneously using TMAs. In addition, representative samples of tumour-free and relatively normal oesophageal tissue were available from > 50% of the resection specimens and were included in the TMAs as controls.
IMMUNOHISTOCHEMICAL STAINING
Formalin-fixed, paraffin-embedded multitumour microarray sections (5 µm thick), X Wang, HT Liu, SL Li et al.
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containing solid tumours and normal oesophageal tissue were immunostained to detect PAR-2 protein. Samples of breast carcinoma were used as a positive control and 0.01 M phosphate-buffered saline solution (PBS), pH 7.2, was used instead of antibody as a negative control. Antigen retrieval was performed at 120°C (in an autoclave) for 5 min in 10 nmol/l sodium citrate buffer (pH 6.0). Endogenous peroxidase activity was blocked with 0.03% hydrogen peroxide solution containing sodium azide at room temperature for 30 min. Sections were then incubated overnight at 4°C with mouse anti-PAR-2 monoclonal primary antibody (1:200 dilution; Invitrogen, Carlsbad, CA, USA). The sections were then washed thoroughly with 0.01 M PBS, pH 7.2. Binding of the primary antibodies was visualized using an EnVision+™ horseradish peroxidase kit (Dako, Glostrup, Denmark) according to the manufacturer's instructions. The intensity of PAR-2 staining was scored as negative (0), weak (+1), positive (+2) or strong (+3). All sections were scored independently by two pathologists in a blinded fashion, i.e. without knowledge of the clinicopathological features or clinical course of the patient. Because scoring was found to be concordant in 95% of cases, the few discordant scores were settled by joint review to achieve consensus.
STATISTICAL ANALYSIS
Statistical analysis was performed using SAS ® software, version 9.1 (SAS Institute, Cary, NC, USA) for Windows ® . Data were analysed using the Pearson's χ 2 -test or the Fisher's exact test to assess associations between PAR-2 immunostaining and clinicopathological parameters. Kaplan-Meier statistics were used to determine the effects of age, sex, disease stage, histological grade and level of PAR-2 immunoreactivity on the clinical outcome, and subgroups were compared using the log-rank test for univariate analysis. The multivariate Cox proportional hazards model was applied using a stepwise forward method to detect independent predictors of survival. Twotailed P-values < 0.05 were considered to be statistically significant.
Results
Clinicopathological features of the tumours and demographic characteristics of the patients from whom they were obtained are shown in Table 1 . There were similar numbers of males and females among the cases included in the study. At the time of surgical resection, the mean age and age range were similar between the two sexes. The mean follow-up period was 49 months (range 1 -82 months 
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Immunohistochemistry staining for PAR-2 in OSCC tissue showed that PAR-2 was diffusely present (brown staining) throughout the cytoplasm and cell membranes. Non-tumorous epithelial cells in normal oesophageal tissues showed a very low level of PAR-2 immunoreactivity (Fig. 1A) . PAR-2 immunoreactivity was observed in 181 (88.3%) of the 205 OSCC specimens.
Of these 181 PAR-2immunoreactive specimens, staining was positive or strong (2+/3+) in 146 (80.7%) and was weak (1+) in 35 (19.3%) . A positive (+2) or strong (+3) level of immunoreactivity was found in 11/24 (45.8%) histologically well differentiated tumours (Fig.  1B) , 62/92 (67.4%) moderately differentiated tumours (Fig. 1C ) and 73/89 (82.0%) poorly differentiated tumours (Fig. 1D) . Immunoreactivity for PAR-2 with a score of +2 or +3 was significantly associated with higher OSCC disease stage (III and IV), both overall (P = 0.035) and for well differentiated (P = 0.032), moderately differentiated (P = 0.019) and poorly differentiated (P = 0.011) tumours ( Table 2 ). In contrast, PAR-2 immunoreactivity was not correlated with sex or age (data not shown). The effect of moderate or high levels of PAR-2 immunoreactivity on cancer-related death was assessed by Kaplan-Meier survival analysis. Univariate analysis revealed a significant correlation between poor clinical outcome (low survival) and high levels of PAR-2 immunoreactivity in patients with OSCC (P = 0.023) (Fig. 2 ).
Discussion
It has been reported that PAR-2 is overexpressed in a variety of malignant X Wang, HT Liu, SL Li et al. PAR-2 and prognosis of oesophageal squamous cell carcinoma neoplasms, including cancers of the breast, stomach, colon, prostate and pancreas. 13 -19 PAR-2 can be activated by trypsin, mast cell tryptase and coagulation factor VIIa-tissue factor complex. 24, 25 It can also be activated in vitro by synthetic peptides that resemble the new sequence (SLIGKV) produced after receptor cleavage. 26 The amino terminaltethered ligand dipeptide sequence S37L38 of PAR-2 plays a major role in activation of the protein. 27 After PAR-2 activation, the physical association with Jun activation domain binding protein (Jab1) mediates c-Jun/activator protein 1. PAR-2 transduces signals through the mitogen-activated protein kinase-extracellular signal-regulated kinase, phospholipase C and protein kinase C pathways. 28, 29 Several biological effects, such as the inflammatory reaction, salivary secretion, pancreatic secretion, vasodilatation, proliferation and the migration of tumour cells, are specific consequences of PAR-2 activation. 18,30 -34 Studies have shown that the activation of PAR-2 can release vascular endothelial growth factor, interleukin (IL)-6 and IL-8 in tumour cell lines, which contribute to the angiogenesis and invasion of malignant neoplasms. 35 -37 Fujimoto et al. 38 found a significant correlation between PAR-2 and trypsin immunostaining with gastric cancer progression. Matej et al. 39 showed that PAR-2 is expressed in breast cancer tissues and in MDA-MB-231 cells, and that its expression is linked to tumour proliferation. Furthermore, other studies in solid tumours, such as pancreatic, gastric and colon cancers, have demonstrated that the proliferation of tumour cells is mediated through the activation of PAR-2 by trypsin or other PAR-2 agonists. 40 In gastric cancer, PAR-2 activation promotes epidermal growth factor receptor transactivation and proliferation, which induces angiogenesis in the tumour. 24 Gene chip and proteome analysis have been used to predict the outcome of patients with cancer. 41 These methods are, however, seldom used in the prognosis of patients with tumours. In contrast, immunohistochemistry has been widely used to predict the prognosis of patients with tumours, 42 which is why it was used in the present study to evaluate the prognosis of patients with oesophageal cancer.
The present study revealed that tumour samples obtained from patients with OSCC showed expression of PAR-2 at different levels: expression was higher in poorly differentiated oesophageal tumours and in stage III or IV tumours compared with normal oesophageal tissue. Moreover, a high level of PAR-2 protein was negatively correlated with survival. The finding that the expression of PAR-2 varied significantly with the stage and histological grade of OSCC is novel. The correlation between the expression of PAR-2, a high tumour stage and poor prognosis observed in the present study is similar to that seen in other neoplasms. 20, 21 In conclusion, levels of PAR-2 protein in tumour tissue correlated specifically with a poor prognosis in patients with OSCC. Overexpression of PAR-2 probably reflects increased potential for tumour invasiveness and metastatic spread, and the detection of increased levels of PAR-2 may, therefore, serve as an important biomarker of aggressive OSCC.
